Funding for this research was provided by:
U.S. President's Malaria Initiative
Received: 27 May 2020
Accepted: 4 August 2020
First Online: 14 August 2020
Ethics approval and consent to participate
: The approval for the TES, which included testing of molecular markers for drug resistance, was obtained from the Kenya Medical Research Institute/Scientific and Ethics Review Unit (KEMRI/SERU). The U.S. Centers for Disease Control and Prevention Institutional Review Board approved reliance on the KEMRI/SERU for this protocol. Written informed consent was obtained from every parent or guardian of each participating child before enrolment.
: Not applicable.
: The authors declare that they have no competing interests.